ADAG · Adagene Inc. American Depositary Shares
View on chartInsiders & Stakes
| Peter Luo Chief Executive Officer | ▲ Buy | Open Market | 88,535 Shares held | 9/16/2026 | View profile |
| Tam Man Kin Chief Financial Officer | ▲ Buy | Open Market | 12,000 Shares held | 9/23/2026 | View profile |
| Cuong Do V President & CEO | ▲ Buy | Open Market | 2,000 Shares held | 8/14/2026 | View profile |
Transaction History
| Tam Man Kin | ▲ Buy | Open Market | 2,000 | $6K | 9/23/2026 |
| Peter Luo | ▲ Buy | Open Market | 20,290 | $64K | 9/16/2026 |
| Cuong Do V | ▲ Buy | Open Market | 2,000 | $8K | 8/14/2026 |
| Peter Luo | ▲ Buy | Open Market | 279 | $1K | 8/5/2026 |
| Peter Luo | ▲ Buy | Open Market | 22,966 | $84K | 8/4/2026 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Adagene's ADG138 IND approved by China's NMPA
China's National Medical Products Administration has cleared Adagene's Investigational New Drug application for ADG138, a HER2xCD3 bispecific T-cell engager. This regulatory step allows the company to proceed with clinical development of its proprietary SAFEbody technology in China. The stock is currently trading near its 52-week low, well below the average analyst target price.
Adagene's ADG138 IND approved by China's NMPA. China's National Medical Products Administration has cleared Adagene's Investigational New Drug application for ADG138, a HER2xCD3 bispecific T-cell engager. This regulatory step allows the company to proceed with clinical development of its proprietary SAFEbody technology in China. The stock is currently trading near its 52-week low, well below the average analyst target price.